Trulicity vs Ozempic: what the head-to-head trial showed

In the only direct head-to-head trial (SUSTAIN-7), Ozempic (semaglutide) beat Trulicity (dulaglutide) on both blood-sugar control and weight loss in type 2 diabetes. At the higher doses, semaglutide lowered HbA1c by about 1.8 percentage points versus about 1.4 for dulaglutide, and produced about 6.5 kg of weight loss versus about 3.0 kg. So on average semaglutide was more effective. "Better" for you still depends on tolerance, cost, insurance, and availability — but on efficacy, the head-to-head favored Ozempic.

Both are once-weekly injections for type 2 diabetes and both are GLP-1 receptor agonists, but they are different molecules — dulaglutide (Trulicity) and semaglutide (Ozempic). In head-to-head testing, semaglutide produced greater A1C and weight reductions. Trulicity's pen is often considered very easy to use (no dose dialing, hidden needle). Both are FDA-approved for diabetes, and both can also reduce cardiovascular risk in appropriate patients — neither is approved for weight loss.

SUSTAIN-7 (Lancet Diabetes & Endocrinology, 2018) randomized about 1,200 adults with type 2 diabetes on metformin to semaglutide or dulaglutide for 40 weeks. Semaglutide 0.5 mg beat dulaglutide 0.75 mg, and semaglutide 1 mg beat dulaglutide 1.5 mg, on both A1C (about −1.5% vs −1.1% at low dose; −1.8% vs −1.4% at high dose) and weight (about −4.6 kg vs −2.3 kg; −6.5 kg vs −3.0 kg). Semaglutide was statistically superior on both measures, with similar overall tolerability.

No. Both are FDA-approved to treat type 2 diabetes, not obesity, even though people often lose weight on them. If weight loss is the goal, the on-label options are different products — Wegovy (semaglutide 2.4 mg) and Zepbound (tirzepatide). Using a diabetes-approved drug off-label for weight loss can also complicate insurance coverage.

If Trulicity is controlling your blood sugar and you tolerate it, there may be no need to change. If your A1C or weight goals aren't being met, the head-to-head data give a reasonable basis to discuss switching to semaglutide with your prescriber. Availability can also factor in — dulaglutide has had periodic supply constraints at some doses. Any switch involves matching doses and is a clinical decision, not a do-it-yourself change.

Confirm coverage for the new drug before you stop the old one — that is the step people skip, and it is where gaps come from. The switch itself is a clinical decision rather than a dose conversion: milligram figures are not comparable between dulaglutide and semaglutide, so your prescriber sets a starting dose on the new drug instead of matching your current strength. Expect early gastrointestinal effects to reappear while you titrate, even though you tolerated your previous drug fine.

For some people, meaningfully so. Trulicity's device is designed so you never handle or see the needle, which matters if injection technique or needle anxiety is a genuine barrier to taking the medication at all. That is a legitimate clinical consideration rather than a minor preference — the more effective drug is not more effective if it goes untaken. If device usability is your main obstacle, say so directly when you discuss options.

Not necessarily. A formulary change is a coverage decision, not a clinical one, and it has its own remedy: if the newly preferred drug is inappropriate for you — because it previously failed, caused intolerable side effects, or is contraindicated — your prescriber can request a formulary exception arguing medical necessity. If that is denied, you have appeal rights. Being switched by a formulary is common, but it is not automatically the end of the discussion.